PE20140409A1 - DERIVATIVES OF 4- (5-CYANO-PIRAZOL-1-IL) -PIPERIDINE AS MODULATORS OF GPR 119 - Google Patents

DERIVATIVES OF 4- (5-CYANO-PIRAZOL-1-IL) -PIPERIDINE AS MODULATORS OF GPR 119

Info

Publication number
PE20140409A1
PE20140409A1 PE2013001058A PE2013001058A PE20140409A1 PE 20140409 A1 PE20140409 A1 PE 20140409A1 PE 2013001058 A PE2013001058 A PE 2013001058A PE 2013001058 A PE2013001058 A PE 2013001058A PE 20140409 A1 PE20140409 A1 PE 20140409A1
Authority
PE
Peru
Prior art keywords
methyl
pirazol
cyane
piperidin
carboxylate
Prior art date
Application number
PE2013001058A
Other languages
Spanish (es)
Inventor
Vincent Mascitti
Kim Francis Mcclure
Michael John Munchhof
Ralph Pelton Robinson Jr
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45418722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140409(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of PE20140409A1 publication Critical patent/PE20140409A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

REFERIDA A UN DERIVADO DE PIPERIDINA TAL COMO: 4-{5-CIANO-4-[(2,4-DIFLUOROFENOXI)METIL]-1H-PIRAZOL-1-IL}PIPERIDIN-1-CARBOXILATO DE ISOPROPILO, 4-{5-CIANO-4-[(2-METILFENOXI)METIL]-1H-PIRAZOL-1-IL}PIPERIDIN-1-CARBOXILATO DE METILCICLOPROPILO, 4-{5-CIANO-4-[(2,3-DIFLUOROFENOXI)METIL]-1H-PIRAZOL-1-IL}PIPERIDIN-1-CARBOXILATO DE METILCICLOPROPILO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS MODULAN LA ACTIVIDAD DEL RECEPTOR GPR119 ACOPLADO A LA PROTEINA G Y SON UTILES EN EL TRATAMIENTO DE LA DIABETES, DISLIPIDEMIAS, ENFERMEDAD VASCULAR PERIFERICA, ENTRE OTRASREFERRED TO A PIPERIDINE DERIVATIVE SUCH AS: 4- {5-CYANE-4 - [(2,4-DIFLUOROPHENOXY) METHYL] -1H-PIRAZOL-1-IL} PIPERIDIN-1-ISOPROPYL CARBOXYLATE, 4- {5- CYANE-4 - [(2-METHYLPHENOXY) METHYL] -1H-PYRAZOL-1-IL} PIPERIDIN-1-CARBOXYLATE METHYL CYCLOPROPYL, 4- {5-CYANE-4 - [(2,3-DIFLUOROPHENOXY) MEthyl] -1H -PYRAZOLE-1-IL} METHYL CYCLOPROPYL PIPERIDIN-1-CARBOXYLATE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS MODULATE THE ACTIVITY OF THE GPR119 RECEPTOR COUPLED TO PROTEIN G AND ARE USEFUL IN THE TREATMENT OF DIABETES, DYSLIPIDEMIAS, PERIPHERAL VASCULAR DISEASE, AMONG OTHERS

PE2013001058A 2010-11-23 2011-11-09 DERIVATIVES OF 4- (5-CYANO-PIRAZOL-1-IL) -PIPERIDINE AS MODULATORS OF GPR 119 PE20140409A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41644110P 2010-11-23 2010-11-23

Publications (1)

Publication Number Publication Date
PE20140409A1 true PE20140409A1 (en) 2014-03-23

Family

ID=45418722

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001058A PE20140409A1 (en) 2010-11-23 2011-11-09 DERIVATIVES OF 4- (5-CYANO-PIRAZOL-1-IL) -PIPERIDINE AS MODULATORS OF GPR 119

Country Status (26)

Country Link
EP (1) EP2643310A1 (en)
JP (1) JP2013543885A (en)
KR (1) KR20130083915A (en)
CN (1) CN103298801A (en)
AP (1) AP2013006809A0 (en)
AR (1) AR088121A1 (en)
AU (1) AU2011333427A1 (en)
BR (1) BR112013011865A2 (en)
CA (1) CA2814231A1 (en)
CL (1) CL2013001054A1 (en)
CO (1) CO6801716A2 (en)
CR (1) CR20130139A (en)
CU (1) CU20130059A7 (en)
DO (1) DOP2013000102A (en)
EA (1) EA201370118A1 (en)
EC (1) ECSP13012630A (en)
GT (1) GT201300135A (en)
MA (1) MA34805B1 (en)
MX (1) MX2013004083A (en)
NI (1) NI201300044A (en)
PE (1) PE20140409A1 (en)
SG (1) SG189830A1 (en)
TW (1) TWI433843B (en)
UY (1) UY33742A (en)
WO (1) WO2012069948A1 (en)
ZA (1) ZA201302362B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6463631B2 (en) 2011-06-09 2019-02-06 ライゼン・ファーマシューティカルズ・エスアー Novel compounds as modulators of GPR-119
CN104780915A (en) 2012-07-11 2015-07-15 埃尔舍利克斯治疗公司 Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
JP2017119628A (en) * 2014-05-09 2017-07-06 日産化学工業株式会社 Substituted azole compound and therapeutic agent for diabetes
CN104610151A (en) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 Compound containing hydrazide and alkoxy benzene structures as well as preparation method and application thereof
CN104892517A (en) * 2015-02-13 2015-09-09 佛山市赛维斯医药科技有限公司 Hydrazine compound, method for preparing same and application of hydrazine compound
CN104592120A (en) * 2015-02-13 2015-05-06 佛山市赛维斯医药科技有限公司 Cyclopropyl hydrazide and methoxybenzene-containing GPR119 agonist as well as preparation method and application thereof
BR112018016794B1 (en) 2016-02-18 2022-07-19 Syngenta Participations Ag ACTIVE PYRAZOLE DERIVATIVES IN TERMS OF PESTICIDES, PESTICIDE COMPOSITION, METHOD FOR CONTROL OF PESTS, METHOD FOR PROTECTING VEGETABLE PROPAGATION MATERIAL FROM PEST ATTACK AND VEGETABLE PROPAGATION MATERIAL
CN106631992B (en) * 2017-01-05 2019-01-18 桑迪亚医药技术（上海）有限责任公司 A kind of synthetic method of 4- oxygen -3,4- dihydro -2H- pyridine -1- t-butyl formate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100033419A (en) * 2007-07-19 2010-03-29 메타볼렉스, 인코포레이티드 N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders
CA2719507C (en) * 2008-03-31 2018-03-27 Metabolex, Inc. Oxymethylene aryl compounds and uses thereof
KR20120061063A (en) * 2009-06-05 2012-06-12 화이자 인코포레이티드 L-(piperidin-4-yl)-pyrazole derivatives as gpr119 modulators

Also Published As

Publication number Publication date
NI201300044A (en) 2013-08-01
CR20130139A (en) 2013-06-28
CL2013001054A1 (en) 2013-09-27
EA201370118A1 (en) 2013-12-30
WO2012069948A1 (en) 2012-05-31
AR088121A1 (en) 2014-05-14
CA2814231A1 (en) 2012-05-31
UY33742A (en) 2012-06-29
ECSP13012630A (en) 2013-07-31
AP2013006809A0 (en) 2013-04-30
EP2643310A1 (en) 2013-10-02
GT201300135A (en) 2015-02-19
AU2011333427A1 (en) 2013-04-11
TWI433843B (en) 2014-04-11
CU20130059A7 (en) 2013-06-28
CN103298801A (en) 2013-09-11
TW201300373A (en) 2013-01-01
JP2013543885A (en) 2013-12-09
CO6801716A2 (en) 2013-11-29
BR112013011865A2 (en) 2016-08-23
KR20130083915A (en) 2013-07-23
MX2013004083A (en) 2013-06-13
MA34805B1 (en) 2014-01-02
ZA201302362B (en) 2014-06-25
DOP2013000102A (en) 2013-07-15
SG189830A1 (en) 2013-06-28

Similar Documents

Publication Publication Date Title
PE20140409A1 (en) DERIVATIVES OF 4- (5-CYANO-PIRAZOL-1-IL) -PIPERIDINE AS MODULATORS OF GPR 119
PE20150626A1 (en) SWEET FLAVOR MODIFIER
CL2008002111A1 (en) COMPOUNDS DERIVED FROM PIRIDONA, AGONISTS OF THE RECEPTOR COUPLED TO PROTEIN G GPR119; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS DIABETES, METABOLIC SYNDROME, CANCER, AMONG OTHERS.
EA201070699A1 (en) COMPOSITIONS 3- (6- (1-2,2-DIFTORBENZO [D] [1,3] DIOXOL-5-IL) CYCLOPROPANKARAROXAMIDO) -3-Methylpyridine-2-il
NZ599343A (en) Substituted piperidines that increase p53 activity and the uses thereof
UY32884A (en) 1-substituted-4- (5- (phenyl or heteroaryl) methoxy) -pyrimidin-2-yl) piperazines and piperidines
EP2217596B8 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
BR112013006344A2 (en) piperdinyl substituted lactams as gpr119 modulators, pharmaceutical composition comprising them, use and process for preparing same
UA111579C2 (en) Heterocyclic 2-Aminobenzo [d] Oxazole Derivatives, Pharmaceutical Composition Based on Them and Their Applications for Disease Treatment
EA201290078A1 (en) HETEROCYCLIC COMPOUNDS TO INHIBIT PASK
CR20130649A (en) MODIFIED RELEASE OF 4-METHYL-3 - [[4- (3-PYRIDINYL) -2-PYRIMIDINYL] -AMINO] -N- [5- (4-METHYL-1H-IMIDAZOL-1-IL) -3- (TRIFLUORO -METIL) -PENYL] -BANZAMIDE SOLUBILIZED USING ORGANIC ACIDS
CL2013002053A1 (en) Heterocyclic derivative compounds, glucagon receptor antagonists; pharmaceutical composition that includes it and its use in the treatment of diabetes and metabolic diseases. pct
CL2008002542A1 (en) Imidazolyl pyridine derived compounds linked to a heterocycle via a vinyl, modulators of amyloid-beta activity; pharmaceutical composition comprising said compounds; and its use for the treatment of diseases such as Alzheimer's, dementia, Down syndrome or amyloidosis.
PE20161363A1 (en) PYRROLIDINE PROTEIN G40 (GPR40) COUPLED RECEPTOR MODULATORS FOR THE TREATMENT OF DISEASES SUCH AS DIABETES
CO6670520A2 (en) Lactmas substituted with piperidinium as modulators of gpr119
IL209719A0 (en) Fviii muteins for treatment of von willebrand disease
EA201170753A1 (en) NALMEPHENA HYDROCHLORIDE DIHYDRATE
EA201100358A1 (en) DABIGATRAN FOR INTERTEGUAL SURGICAL CATHETERIZATION OF THE HEART
CL2011003079A1 (en) Aromatic or heteroaromatic derivative compounds of oxime nitrogenous heterocycles, gpr119 receptor agonist; pharmaceutical composition comprising said compounds; and its use for the treatment of diseases mediated by the modulation of said activity, such as obesity and diabetes.
CL2013002412A1 (en) Compounds derived from (piperidin-4-yl) -ureas; pharmaceutical composition; and use as antagonists of the ghrelin receptor in the treatment of obesity, eating disorders, diabetes, cachexia caused by cancer, congestive heart failure, among others.
EA201291167A1 (en) SUBSTITUTED HETEROCYCLYLBENZYLPYRAZOLES AND THEIR APPLICATION
CR11600A (en) INDAZOL DERIVATIVES
CL2008002689A1 (en) Compounds derived from heterocycle 1,4 substituted piperidine; intermediate compounds; pharmaceutical composition; Preparation process; and its use in the treatment of Alzheimer's and schizophrenia.
CL2015000891A1 (en) Phenyl-ethynyl derivative compounds, modulators of the activity of the mglur5 receptor; Preparation process; pharmaceutical composition; and use in the treatment of anxiety, pain, depression, among others.
PE20121538A1 (en) THERAPEUTIC COMBINATIONS OF THEOBROMINE AND AN ANTIHISTAMINE

Legal Events

Date Code Title Description
FD Application declared void or lapsed